Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as R906289 Monosodium (R289 Na)
R906289 Monosodium · 1 trial · 1 indication
* Incidence of adverse events (AEs) * Incidence of discontinuation or interruptions of R289 due to AEs * Incidence of dose limiting toxicities (DLTs)
| Arm | Type | Description |
|---|---|---|
| Experimental | EXPERIMENTAL | ESCALATION PHASE: Dose Level 1: 250mg PO qd Dose Level 2: 500mg PO qd Dose Level 3: 750 mg PO qd Dose Level 4: 250 mg PO bid Dose Level 5: 500 mg PO AM/250 mg PO PM Dose Level 6: 500 mg PO bid EXPANSION PHASE (randomized 1:1): Dose Level 1: 250 mg PO qd Dose Level 2: 250 mg PO bid |
| Name | Type | Description |
|---|---|---|
| R906289 Monosodium (R289 Na) | DRUG | Drug: R906289 Monosodium (R289 Na) R906289 Monosodium (250mg PO qd, 250mg PO bid, 500 mg PO qd, 500 mg PO bid, 750 mg PO qd, split dose - 500 mg PO AM/250 mg PO PM) |
Inclusion Criteria: * Patient must be ≥ 18 years of age at the time of signing the informed consent. * Must have definitive diagnosis of MDS with very low, low, or intermediate-1 risk (International Prognostic Scoring System (IPSS)-R ≤ 3.5) and ≤5% bone marrow myeloblasts. * Must be relapsed, refra...
Top 20 of 33 competitors
R906289 Monosodium, also known as R289 Na, is an investigational small molecule being developed for the treatment of low risk myelodysplastic syndromes. It is currently in Phase 1 clinical development and has not been approved by the FDA.
R906289 Monosodium targets IRAK1 and IRAK4, which are kinases involved in inflammatory signaling pathways. By inhibiting these targets, the drug aims to address the underlying biology of low risk myelodysplastic syndromes.
R906289 Monosodium is being developed by Rigel Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol RIGL. The company is conducting clinical trials to evaluate the drug's safety and efficacy.
R906289 Monosodium is in Phase 1 clinical development. It is an investigational drug being studied in patients with low risk myelodysplastic syndromes, and it is not yet approved for commercial use.
R906289 Monosodium is being evaluated in a Phase 1 clinical trial with the identifier NCT05308264. This open-label, uncontrolled study is recruiting approximately 86 participants with low risk myelodysplastic syndromes at sites in the United States.
Yes, R906289 Monosodium is also known as R289 Na. Both names refer to the same investigational drug being developed by Rigel Pharmaceuticals for the treatment of low risk myelodysplastic syndromes.